Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
← catalyst calendarSponsored by Annexon, Inc. (industry) · ANNX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
7actual
Sites
4
Countries
Australia, Austria, Bulgaria +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-10 | actual | When the study began enrolling |
| Primary completion | 2023-01-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2023-01-17 | actual | The whole study's end, after follow-up |
| First posted | 2020-12-31 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-30 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Warm Autoimmune Hemolytic Anemia (wAIHA)
Intervention
- Drug: ANX005
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
measured Day 1 through Day 71
Maximum Change From Baseline in Hemoglobin Levels
measured Baseline up to Day 71
Change From Baseline in Lactate Dehydrogenase Levels at Day 71
measured Baseline, Day 71
Change From Baseline in Percentage of Reticulocytes/Total Cells Count at Day 71
measured Baseline, Day 71
Change From Baseline in Haptoglobin Levels at Day 71
measured Baseline, Day 71
Change From Baseline in Total Bilirubin Levels at Day 71
measured Baseline, Day 71
Change From Baseline in Indirect Bilirubin Levels at Day 71
measured Baseline, Day 71
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-03-23 · 972 KB · Prot_000.pdf
Statistical Analysis Planposted 2022-12-22 · 887 KB · SAP_001.pdf
Related
ANNX's other studiesmost recently updated first
- An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease Phase 2 · Completed
- An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Phase 3 · Recruiting
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Phase 3 · Active, not recruiting
- Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome Phase 3 · Completed
- Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2 · Completed
Permalink · ANNX's whole pipeline · Catalyst calendar · Every registered study · What changed